A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Exclusion Criteria

• •Diagnosed with cancers of predominantly non-squamous histology (eg, adenosquamous carcinoma) or adenocarcinoma.
• •Has received antineoplastic therapies prior to study intervention within specified time frame.
• •Has rapidly progressing disease (eg, tumor bleeding, uncontrolled tumor pain).
• •Patients with uncontrolled diabetes.
• •Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• •Has clinically significant gastrointestinal bleeding and has an active infection requiring systemic treatment and has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the clinical study, interfere with the patient's participation for the full duration of the clinical study, or is not in the best interest of the patient to participate.
• •Concomitant use of drugs that are known to prolong or shorten QT and/or have known risk of Torsades de Pointes.